Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)

Next Previous
Search
Trial Profile

A Phase 2 Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Oct 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Rituximab
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Post-transplant lymphoproliferative disorder
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Seagen; Seattle Genetics

Most Recent Events

  • 04 Jun 2019 Results assessing CD30 expression level to predict response to brentuximab vedotin by using data from five studies including this study presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
  • 03 Jun 2019 Results of an exploratory analysis using data integrated from 275 patients with peripheral T-cell lymphoma, cutaneous T-cell lymphoma, and B-cell lymphoma treated with Brentuximab vedotin from 5 prospective clinical trials (NCT01421667, NCT02588651, NCT01578499, NCT01352520, NCT01396070) presented in a Seattle Genetics media release.
  • 19 Oct 2015 Data of DLBCL patients who received single agent ADCETRIS or in combination with Rituxan every three weeks were published in a Seattle Genetics media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top